Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study.

Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nežádal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Akcicek H, Tassorelli C

Open source

DOI: 10.1007/s10072-025-08484-1
Published: 2025 Dec
Container: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10072-025-08484-1,
  title = {Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study.},
  author = {Ashina M and Mitsikostas DD and Amin FM and Kokturk P and Schankin CJ and Sahin G and Pozo-Rosich P and Dorman PJ and Nežádal T and Poole AC and Martins IP and Sumelahti ML and Ramirez Campos V and Ahn AH and Akcicek H and Tassorelli C},
  year = {2025},
  journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
  doi = {10.1007/s10072-025-08484-1},
  url = {https://doi.org/10.1007/s10072-025-08484-1}
}

RIS

TY  - JOUR
TI  - Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study.
AU  - Ashina M
AU  - Mitsikostas DD
AU  - Amin FM
AU  - Kokturk P
AU  - Schankin CJ
AU  - Sahin G
AU  - Pozo-Rosich P
AU  - Dorman PJ
AU  - Nežádal T
AU  - Poole AC
AU  - Martins IP
AU  - Sumelahti ML
AU  - Ramirez Campos V
AU  - Ahn AH
AU  - Akcicek H
AU  - Tassorelli C
PY  - 2025
JO  - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
DO  - 10.1007/s10072-025-08484-1
UR  - https://doi.org/10.1007/s10072-025-08484-1
ER  -

APA

M, A., DD, M., FM, A., P, K., CJ, S., G, S., P, P., PJ, D., T, N., AC, P., IP, M., ML, S., V, R. C., AH, A., H, A., & C, T. (2025). Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://doi.org/10.1007/s10072-025-08484-1

Source records

pubmed · retrieved 2026-09-25T10:44:50.895Z